Tenacia, Rapport Strike $308M China Epilepsy Deal
March 9, 2026
Tenacia Therapeutics inks a deal worth up to 308 million USD for China rights to Rapport’s experimental epilepsy drug, extending Western CNS innovation into the China market.
March 9, 2026
Tenacia Therapeutics inks a deal worth up to 308 million USD for China rights to Rapport’s experimental epilepsy drug, extending Western CNS innovation into the China market.